What's Happening?
ADC Therapeutics experienced a significant drop in its share price following the disclosure of patient deaths in a trial of its drug Zynlonta. The phase 3 LOTIS-5 trial, involving patients with relapsed or refractory diffuse large B-cell lymphoma, reported
27 deaths in the study arm compared to nine in the control group. The deaths, primarily among older patients, were attributed to infections. Despite achieving its primary endpoint of progression-free survival, the trial's adverse events overshadowed the positive results. ADC plans to meet with the FDA to discuss the trial outcomes and seek approval for expanded use of Zynlonta.
Why It's Important?
The trial results have significant implications for ADC Therapeutics, as Zynlonta is its only commercial product. The reported deaths and adverse events raise concerns about the drug's safety profile, potentially affecting its marketability and future sales. The share price drop reflects investor apprehension about the company's prospects. The outcome of the upcoming FDA meeting will be crucial for ADC's strategy to expand Zynlonta's use and secure its financial stability. The situation highlights the challenges pharmaceutical companies face in balancing efficacy and safety in drug development.
What's Next?
ADC Therapeutics plans to meet with the FDA in August to discuss the trial results and its strategy for seeking approval for Zynlonta's expanded use. The company is also conducting the LOTIS-7 trial, investigating Zynlonta in combination with another drug for B-cell non-Hodgkin lymphoma. The outcomes of these discussions and trials will be pivotal in determining ADC's future direction and its ability to recover from the current setback.
